Remedy Pharmaceuticals’ Edema and Neuro-inflammation Advisory Board Provides Guidance on Opportunities in CNS Conditions
NEW YORK, New York, August 18, 2016 — Remedy Pharmaceuticals, a privately-held phase 3-ready pharmaceutical company focused on bringing life-saving hospital-based treatment to people affected by central nervous system related edema, today announced the successful conclusion of a two-day scientific advisory board meeting in which a distinguished panel of experts provided recommendations on promising indications for the Company to consider pursuing in addition to its current programs.
“This meeting underscores our commitment to continuing the development of innovative therapies for severe conditions where edema is a significant driver of clinical outcomes," says Sven Jacobson, CEO of Remedy Pharmaceuticals.
Scientific advisors in attendance included (alphabetically) Daniel Hanley, M.D., Professor, Acute Care Neurology, Director, Division of Brain Injury Outcome Services, The Johns Hopkins Medical Institutions; Minesh Mehta, M.D., Director, Radiation Oncology and Deputy Director, Miami Cancer Institute, Baptist Health, Adjunct Professor, Radiation Oncology, University of Maryland College of Medicine; Michael Moskowitz, M.D., Professor of Neurology, Harvard College in Medicine, Neuroscientist, Dept. Neurology and Radiology, Massachusetts General Hospital; Graham Nichol, M.D., MPH, Professor of Medicine, University of Washington College of Medicine, Chair in Prehospital Emergency Care, Medical Director, Resuscitation Outcome Consortium Clinical Trial Center; Raymond Sawaya, M.D., Professor and Chairman, Dept. of Neurosurgery, University of Texas, MD Anderson Cancer Center, Adjunct Professor, Baylor College of Medicine; and J. Marc Simard, M.D., Ph.D, Professor of Neurosurgery, Pathology and Physiology, University of Maryland, College of Medicine and Scientific Founder of Remedy Pharmaceuticals.
“After participating in Remedy Pharmaceuticals’ advisory board meeting, I believe CIRARA has a wide range of possible neuroinflammatory benefits that each deserve vigorous and detailed evaluation,” comments Daniel Hanley, M.D., Director, Division of Brain Injury Outcome Services, The Johns Hopkins Medical Institutions.
“Edema is a major source of morbidity in a number of neurological disorders. [In brain cancer] most common therapy involves the use of corticosteroids that are known to cause significant side effects,” states Raymond Sawaya, M.D., Professor and Chairman of the Department of Neurosurgery at MD Anderson Cancer Center. “It is therefore with much anticipation, that Remedy’s drug, CIRARA, has shown great promise in reducing edema in both pre-clinical models as well as in clinical trials.”
“This advisory board serves to complement and further inform our scientific direction and clinical objectives,” notes David Geliebter, Executive Chairman of Remedy Pharmaceuticals. “We are thrilled to have attracted such prominent physicians and scientists who share our interest in this transformative science.”
ABOUT REMEDY PHARMACEUTICALS
Remedy Pharmaceuticals, Inc. is a privately-held, clinical stage pharmaceutical company focused on developing and bringing lifesaving treatment to people affected by acute central nervous system (CNS) edema – including large hemispheric infarction, subarachnoid hemorrhage, and contusional traumatic brain injury, as well as other ischemic injuries and neurological disorders.
212-586-2226 x 225